The MARMADE project aims to develop sustainable, high-value food and feed ingredients from marine biomass, focusing on crustacean residues (shrimp shells and blue crabs) and seaweed.
This proposal will test the efficacy of the GABAB receptor agonist, R-Baclofen, on compulsive alcohol consumption, considering sex as a biological factor in an animal model of interindividual heterogeneity.
The objective of the project is the clinical development of Cebranopadol for the treatment of opioid addiction. The project may be funded by the NIH-NIDA, and the study will be conducted in collaboration with Park Therapeutics, the company that holds the property rights to the molecule.
Aim of the project is to evaluate the therapeutic potential of a new synthetic molecule, called BU10119, for the treatment of alcohol addiction. This molecule acts as a NOP agonist and MOP antagonist.
